Electrospun poly(ε-caprolactone) nanofibrous mesh for imiquimod delivery in melanoma therapy

Abstract

Drug delivery systems (DDS) are commonly employed to administer drug-loaded composites to their therapeutic targets both in vitro and in vivo. Thus, we herein report the study of imiquimod-poly(ε-caprolactone) (IMQ-PCL) nanofibrous meshes for application in melanoma therapy. The preparation route employed was based on the electrospinning technique, with the melanoma cells being cultured on electrospun nanofibrous meshes to study their biocompatibility. All parameters employed, including the flow rate and polymer solution concentration, were examined to gain an improved understanding of the factors influencing the diameter and morphology of the electrospun fibre. The optimised parameters were employed to produce 12 IMQ-PCL nanofibrous meshes with diameters ranging from 100 to 900 nm to the melanoma cell viability. The relationship between the fibrous diameter and the imiquimod release profile was also determined using UV-Vis spectroscopy. In addition, similar results were obtained for the simulated imiquimod release profile obtained by COMSOL Multiphysics®. The IMQ-PCL nanofibrous meshes were found to decrease cell viability by ≥50%, with the number of cells dropping by ~10% over 48 h. As the cell viability was affected by the release of imiquimod, we believe that IMQ-PCL nanofibrous meshes are a promising drug delivery system for application in melanoma therapy.